Undervalued Drug Manufacturer Stocks on NAS July 2023

July 29, 2023

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
VTRS Viatris 10.40 12.00 15.38 7433446 12538 4.62 6.6
AZN AstraZeneca 71.33 79.12 10.92 6931871 222550 2.03 36.1
EVO Evotec 12.63 13.83 9.47 19016 4463 0.00 0.0
IRWD Ironwood Pharmaceuticals 11.05 11.95 8.13 1657508 2063 0.00 11.1
SNY Sanofi 52.48 55.82 6.37 1227962 131127 3.62 13.8
HCM HUTCHMED (China) 14.72 15.30 3.94 101947 2494 0.00 0.0
ALKS Alkermes 28.76 29.69 3.24 1467371 4934 0.00 50.5
BIIB Biogen 265.23 270.41 1.95 1424119 38591 0.00 14.5
INDV Indivior 22.77 22.98 0.94 9472 3250 0.00 0.0
All data provided as at market close July 27, 2023.

Company Details

Viatris

VTRS:NAS

Close Price

10.40

Our Valuation

12.00

% Difference

15.38

Market Cap ($M)

12538

P/E Ratio

6.6

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales.

Access the stockcalc valuation


AstraZeneca

AZN:NAS

Close Price

71.33

Our Valuation

79.12

% Difference

10.92

Market Cap ($M)

222550

P/E Ratio

36.1

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one-third of its sales.

Access the stockcalc valuation


Evotec

EVO:NAS

Close Price

12.63

Our Valuation

13.83

% Difference

9.47

Market Cap ($M)

4463

P/E Ratio

0.0

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate.

Access the stockcalc valuation


Ironwood Pharmaceuticals

IRWD:NAS

Close Price

11.05

Our Valuation

11.95

% Difference

8.13

Market Cap ($M)

2063

P/E Ratio

11.1

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Sanofi

SNY:NAS

Close Price

52.48

Our Valuation

55.82

% Difference

6.37

Market Cap ($M)

131127

P/E Ratio

13.8

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron.

Access the stockcalc valuation


HUTCHMED (China)

HCM:NAS

Close Price

14.72

Our Valuation

15.30

% Difference

3.94

Market Cap ($M)

2494

P/E Ratio

0.0

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Access the stockcalc valuation


Alkermes

ALKS:NAS

Close Price

28.76

Our Valuation

29.69

% Difference

3.24

Market Cap ($M)

4934

P/E Ratio

50.5

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources.

Access the stockcalc valuation


Biogen

BIIB:NAS

Close Price

265.23

Our Valuation

270.41

% Difference

1.95

Market Cap ($M)

38591

P/E Ratio

14.5

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017.

Access the stockcalc valuation


Indivior

INDV:NAS

Close Price

22.77

Our Valuation

22.98

% Difference

0.94

Market Cap ($M)

3250

P/E Ratio

0.0

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Viatris and AstraZeneca are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-july-2023
Viatris $VTRS and AstraZeneca $AZN are the most undervalued Drug Manufacturers stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-july-2023
Viatris and AstraZeneca are the most undervalued Drug Manufacturers stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nas-july-2023

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.